Clinical Trial Update: Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

View source ↗

Summary

The update reports that Janssen's talquetamab for relapsed or refractory multiple myeloma has been approved for marketing under a pre-approval access program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Status: APPROVED_FOR_MARKETING